Global Hemoglobinopathy Testing Services Market Growth (Status and Outlook) 2024-2030

Global Hemoglobinopathy Testing Services Market Growth (Status and Outlook) 2024-2030

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. Hemoglobin is present in the red blood cells that transports oxygen from the lung to the body.

The global Hemoglobinopathy Testing Services market size is projected to grow from US$ 966 million in 2024 to US$ 1685 million in 2030; it is expected to grow at a CAGR of 9.7% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Hemoglobinopathy Testing Services Industry Forecast” looks at past sales and reviews total world Hemoglobinopathy Testing Services sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemoglobinopathy Testing Services sales for 2023 through 2029. With Hemoglobinopathy Testing Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemoglobinopathy Testing Services industry.

This Insight Report provides a comprehensive analysis of the global Hemoglobinopathy Testing Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Hemoglobinopathy Testing Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hemoglobinopathy Testing Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemoglobinopathy Testing Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemoglobinopathy Testing Services.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Hemoglobinopathy Testing Services market by product type, application, key players and key regions and countries.

Segmentation by Type:
Hydroxyurea
Glutamine
Zynteglo
Luspatercept
Others

Segmentation by Application:
Sickle Cell Diseases
Thalassemia
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Hydroxyurea
Glutamine
Zynteglo
Luspatercept
Others

Segmentation by Application:
Sickle Cell Diseases
Thalassemia
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
AstraZeneca
Bluebird Bio
Bristol-Myers Squibb
Emmaus Medical
Acceleron Pharma
HemaQuest Pharmaceuticals
Eli Lilly and Company
Celgene Corporation

Please note: The report will take approximately 2 business days to prepare and deliver.